Why Levothyroxine Stops Working (The Conversion Problem Nobody Tests)

Most people on levothyroxine think their thyroid problem is solved once their TSH comes back in range. Their doctor runs the test, the number looks normal, and the prescription gets refilled. But for a significant portion of those patients, symptoms never fully go away, and the reason why has almost nothing to do with the thyroid itself.

To understand why, you need to see the whole system first.

Your thyroid gland produces two main hormones: T4 and T3. T3 is the active form, the one that actually enters your cells and drives your metabolism, your energy production, your mood, your temperature regulation. T4 is largely inactive on its own. Think of T4 as a shipping container and T3 as the actual goods inside. The container has to be opened before anything useful happens.

Here is where most people's understanding stops. The thyroid only produces about 20% of the T3 that circulates in your blood on any given day. The other 80% gets made somewhere else entirely.

That 80% comes from a conversion process that happens in your liver, your kidneys, and your gut. Specialized enzymes called deiodinases, which are proteins that strip an iodine atom off of T4 to produce the active T3 your cells can use, handle this conversion continuously throughout the day. Without this process working properly, you could have plenty of T4 floating around and still be functionally deficient in the hormone your body actually runs on.

This is the architecture that levothyroxine was designed around. Levothyroxine is synthetic T4, and the treatment logic is sound in principle: give the body T4, and the deiodinase system handles the rest. For many people, this works exactly as intended.

But the assumption baked into that logic is that conversion is happening normally, and that assumption is almost never tested.

When your doctor checks your TSH, which stands for thyroid stimulating hormone, they are measuring what your pituitary gland is signaling to your thyroid. The pituitary acts as a feedback sensor, and when it detects enough thyroid hormone, it reduces its signal. So a normal TSH says the pituitary is satisfied. It says almost nothing about whether the rest of your body is converting T4 into usable T3 at the tissue level.

A 2022 analysis in The Lancet Diabetes and Endocrinology found that patients treated with levothyroxine who had completely normal TSH levels showed T3 to T4 ratios 15 to 20% lower than untreated people in the general population. Up to 40% of those patients still reported symptoms despite their labs looking fine. The pituitary said everything was normal. The peripheral conversion system told a different story.

The deiodinase enzymes at the center of this process are something called selenoproteins, which means they are built from selenium and cannot function properly without it. Selenium deficiency directly impairs T4 to T3 conversion, and research in pediatric patients with selenium deficiency showed measurably elevated free T4 to T3 ratios, exactly what you would predict if the conversion machinery was running below capacity.

But selenium deficiency is not the only thing that disrupts these enzymes. Chronic inflammation downregulates deiodinase activity. Liver dysfunction reduces the organ's conversion capacity directly. Gut dysbiosis interferes with the intestinal component of peripheral conversion. Any one of these can quietly reduce how much T3 your body is actually making from the T4 in your bloodstream, and none of them show up on a standard TSH test.

For people with Hashimoto's thyroiditis, this becomes a compounding problem. Hashimoto's is an autoimmune condition where the immune system attacks thyroid tissue, and the ongoing inflammatory environment that characterizes the disease independently suppresses deiodinase activity. So the disease reduces both the 20% of T3 the thyroid makes directly and disrupts the enzymatic system responsible for the other 80%. The two deficits stack on top of each other, and a normal TSH masks both of them.

There is also a genetic layer to this. Between 12 and 36% of people carry a variant in something called the DIO2 gene, which codes for one of the primary deiodinase enzymes involved in peripheral conversion. People with this variant have reduced conversion efficiency at the tissue level. A 2009 study in the Journal of Clinical Endocrinology and Metabolism found that patients with this DIO2 variant showed measurably worse psychological well-being on T4 monotherapy and responded better when T3 was added to their regimen. Their conversion problem was written into their biology from the beginning, which means no dose of levothyroxine alone fully compensates for it.

This is not a rare edge case. In a large online survey of hypothyroid patients, a substantial portion reported persistent symptoms on T4 therapy despite normalized TSH, and dissatisfaction with their treatment was prominent across the group. The pattern is consistent enough that it points to a systemic gap in how thyroid function is evaluated rather than individual variation that can be dismissed.

The practical implication is straightforward. If you are on levothyroxine and still experiencing fatigue, cognitive fog, cold intolerance, weight resistance, or mood changes despite a normal TSH, the next step is asking your doctor to run a free T3 level alongside TSH. Free T3 measures the unbound, biologically active fraction of T3 in your blood and gives you a direct window into whether conversion is actually producing what your body needs. TSH alone cannot tell you that.

If free T3 comes back low or on the low end of normal, there are two directions the conversation can go. Supporting the deiodinase system with selenium, around 200 micrograms per day, is a reasonable first step because the enzymes cannot do their job without adequate substrate to work from. The other direction is discussing whether combination therapy, meaning T4 plus some form of T3, makes more sense for your situation, particularly if you carry the DIO2 variant or have factors like chronic inflammation or liver stress that limit peripheral conversion.

The deeper point here is about what a lab test actually measures versus what you actually need. TSH tells you how one feedback sensor in one gland is responding to circulating hormone levels. It does not tell you how your liver is converting T4, how your gut is contributing to that conversion, whether your deiodinase enzymes have the selenium they require to function, or whether your genetics limit your conversion capacity to begin with.

Treating a normal TSH as proof that thyroid function is optimized is like checking the fuel gauge on a car and concluding the engine is fine. The gauge measures one thing. The engine is doing something else entirely.

---

References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;11610:2571-2579. PMID: 17016550. Source
2. Endotext NCBI Bookshelf. Thyroid Hormone Synthesis and Secretion: "The thyroid gland produces approximately 20% of total daily T3 production, with the remaining 80% arising from peripheral deiodination of T4." Source
3. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022;10(5):366-372. DOI: 10.1016/S2213-8587(22)00004-3.
4. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2019;295:707-721. PMID: 29620972. Source
5. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy. JCEM. 2009;945:1623-1629. PMID: 19190113. Source
6. Kobayashi R, Hasegawa Y, Kawaguchi T, et al. Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio. Clin Pediatr Endocrinol. 2021;30(1):19-26. DOI: 10.1297/cpe.30.19.
7. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. PMID: 28255299. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness